EMA validates Marketing Application for fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) for HIV treatment
29 May 2015 | By Victoria White
Gilead’s MAA for a fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) has been fully validated and is now under evaluation by the EMA..